Skip to main content

Table 2 Comparison of laboratory values and disease severity before and after Anti-IL-1 therapy

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

 

Before treatment

After treatment

p

Attack frequency (per 3 months)

3 (1–6)

0 (0–1)

.00*

Patients-VAS (0–10 cm)

10 (9–10)

2 (0–3)

.00*

Physicians-VAS (0–10 cm)

9 (8–10)

1 (0–2)

.00*

ESR (mm/h)

33 (9–85)

29 (2–106)

.00*

CRP (mg/dl)

16 (1–80)

2 (1–12)

.00*

GFR (ml/min/m2)

54 (13–180)

42 (10–174)

.592

Durations of attacks (hours)

48 (36–96)

8 (0–24)

0.0*

Proteinuria (mg/day)

3200 (0.5–11.2)

1850 (0.1–12.2)

0.140

 GFR ≥ 60 ml/min/m2

2390 (1400–7200)

890 (120–2.75)

0.008*

 GFR < 60 ml/min/m2

4472 (1950–11.2)

3960 (2050–12.2)

0.345

  1. Values presented as median (minimum-maximum).VAS Visual Analogue Scale (0–10 cm), CRP C reactive protein, GFR glomerul filtration rate, ESR Erythrocyte Sedimentation Rate *: p < 0.05
Back to article page

Advances in Rheumatology

ISSN: 2523-3106